CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling

CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling

Abstract Background Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Sorafenib is the first-line treatment for advanced HCC, but the anti-cancer effects remain to be improved as indicated by its low response rates and failure to prolong the progression-...

Full description

Bibliographic Details
Main Authors: Zibo Chen, Tao Yuan, Fangjie Yan, Song Ye, Qin Xie, Bo Zhang, Nengmin Lin, Qiaojun He, Bo Yang, Hong Zhu
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Cancer
Subjects:
CT707
Sorafenib resistance
YAP
Hypoxia
Hepatocellular Carcinoma
Online Access:https://doi.org/10.1186/s12885-022-09520-5

Internet

https://doi.org/10.1186/s12885-022-09520-5

Similar Items